MammaPrint
MammaPrint is a molecular cancer prognostic test used in breast cancer to estimate the risk of distant metastasis. It analyzes a 70-gene expression signature to classify a tumor as low risk or high risk for metastatic spread within five to ten years after diagnosis. The test is intended to inform adjuvant chemotherapy decisions for patients with early-stage disease.
The test was developed by Dirk van’t Veer and colleagues at Erasmus Medical Center in Rotterdam and
How MammaPrint works centers on extracting RNA from tumor tissue and profiling gene expression to yield a
Clinical validation includes retrospective studies and prospective trials. A key study, the MINDACT trial, assessed whether
Regulatory status and use vary by region. MammaPrint is CE-marked for use in several jurisdictions and is